Last reviewed 2026-05-14 · How we verify

Gonadotrophin Releasing Hormone

Gonadotrophin Releasing Hormone is a GnRH agonist Biologic drug developed by NRG Oncology. It is currently in Phase 3 development for Hormone-sensitive prostate cancer, Hormone-sensitive breast cancer. Also known as: AY-24031, D-His-6-Pro-8-NEt-LHRH, Follicle Stimulating Hormone-Releasing Factor, GN-RH.

Gonadotropin-releasing hormone (GnRH) agonists stimulate the pituitary gland to release luteinizing hormone and follicle-stimulating hormone, which initially increases sex hormone production before causing downregulation and suppression of testosterone and estrogen.

Gonadotropin-releasing hormone (GnRH) agonists stimulate the pituitary gland to release luteinizing hormone and follicle-stimulating hormone, which initially increases sex hormone production before causing downregulation and suppression of testosterone and estrogen. Used for Hormone-sensitive prostate cancer, Hormone-sensitive breast cancer.

At a glance

Mechanism of action

GnRH agonists bind to GnRH receptors on pituitary gonadotroph cells, causing an initial surge in LH and FSH release. With continuous exposure, the pituitary becomes desensitized and GnRH receptor expression decreases, resulting in sustained suppression of gonadal sex hormone production. This hormonal castration effect is used therapeutically in hormone-sensitive cancers and certain reproductive conditions.

Approved indications

• Hormone-sensitive prostate cancer
• Hormone-sensitive breast cancer

Common side effects

• Hot flashes
• Decreased libido
• Erectile dysfunction
• Injection site reactions
• Fatigue
• Gynecomastia

Key clinical trials

• Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments (NA)
• Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma (PHASE2)
• CaREFREE Study (Calorie Restriction, Environment and Fitness: Reproductive Effects Evaluation Study) (NA)
• A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer (PHASE2)
• A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (PHASE2)
• Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients (PHASE2)
• Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
• PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Gonadotrophin Releasing Hormone CI brief — competitive landscape report
• Gonadotrophin Releasing Hormone updates RSS · CI watch RSS
• NRG Oncology portfolio CI

Frequently asked questions about Gonadotrophin Releasing Hormone

Related

• Drug class: All GnRH agonist drugs
• Target: All drugs targeting GnRH receptor
• Manufacturer: NRG Oncology — full pipeline
• Therapeutic area: All drugs in Oncology
• Indication: Drugs for Hormone-sensitive prostate cancer
• Indication: Drugs for Hormone-sensitive breast cancer
• Also known as: AY-24031, D-His-6-Pro-8-NEt-LHRH, Follicle Stimulating Hormone-Releasing Factor, GN-RH, GnRH
• Compare: Gonadotrophin Releasing Hormone vs similar drugs
• Pricing: Gonadotrophin Releasing Hormone cost, discount & access